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Background. There are few data on anakinra use after failure of conventional medications for crystal-induced peripheral arthritis
and/or crowned dens syndrome among complex hospitalized patients. Methods. We retrospectively analyzed the outcome of six
patients affected with subacute crystal-induced arthritis who had received anakinra in second or third line therapy, including three
patients with crowned dens syndrome and three others with gouty arthritis. Patients’ comorbidities, reasons for anakinra use and
associated drugs, and outcomes were recorded. Results. All patients presented with elevated inflammatory syndrome, systemic
symptoms with poly/oligoarthritis. Except for absolute contraindications, all patients were previously treated with full or decreased
dose of NSAID, colchicine, and/or glucocorticoids, with unsatisfactory response. All three gouty patients exhibited complete
responses in all acute involvements under anakinra within 3 to 5 days, including one of them who needed the reintroduction
of colchicine treatment that was previously unsuccessful. Crowned dens syndrome patients, including two with pseudogout and
one with subacute hydroxyapatite deposition disease, needed 9 to 11 days to achieve complete response. Tolerance to anakinra was
good. Conclusion. In case series of complex hospitalized patients, anakinra showed good activity in crowned dens syndrome and
associated crystal-induced peripheral arthritis, with longer treatment duration than in gouty arthritis.
1. Introduction
The number of therapeutic drugs used to treat crystal-
induced arthritis (CRIA) is relatively limited, relying on
colchicine, nonsteroidal anti-inflammatory drugs, and cor-
ticosteroids. These drugs may have significant and severe
side-effects or may be contraindicated and therefore cannot
always be used at an optimal dosage especially among elderly
patients.Thus, other therapeutic options are often required in
clinical practice.
Recently, several publications have focused on the ratio-
nale and efficacy of the interleukin-1 blockade mainly in gout
[1–4] and sparsely in pseudogout [5–7]. No clear outcome
parameters concerning notably the treatment duration of
anakinra are defined. Otherwise, there is no report on the
use of anakinra in the acute inflammatory manifestations of
hydroxyapatite deposition disease (HADD) and notably in
crowned dens syndrome, which is a clinical form that this
latter shares with pseudogout. Both diagnosis and manage-
ment of crowned dens syndrome can be challenging, and the
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control of the disease requires sometimes the combination
of several drugs, with increased risk of toxicity especially in
older patients.
Herein, we report on the successful use of anakinra in
the context of resistance or contraindications to conventional
drugs, in six complex hospitalized elderly patients with
crowned dens syndrome and associated crystal-induced peri-
pheral arthritis (𝑛 = 3) and gouty polyarthritis on the other
hand (𝑛 = 3).
2. Patients and Methods
We retrospectively collected data from six adult patients who
had received off-label anakinra (Kineret 100mg/day; subcu-
taneous injection) for CRIA (gout, pseudogout, or HADD)
between January 2012 and March 2013. All patients included
in this study were hospitalized or referred to the department
of internal medicine. Approvals from institutional medical-
pharmaceutical committee and review board were obtained
for this study, and the patients’ consent was obtained after
providing them with information about anakinra.
The diagnosis of gout was based on the presence of
monosodium urate (MSU) crystals in synovial fluid, the
presence of tophus, or the presence of at least six of the
twelve other crystal-induced types of arthritis referred to in
the criteria of the American College of Rheumatology [8].
The diagnosis of other types of CRIA was based on the same
scheme, except for the characteristic signs of gout, including
hydroxyapatite crystals for HADD or calcium pyrophosphate
(CPP) crystals for pseudogout.
In the setting of complex hospitalized patients, diag-
nosis of an attack of CRIA was based on the presence of
compatible clinical signs, significant increase in C-reactive
protein levels (CRP; normal < 5mg/L) to at least 15mg/L, and
associated typical imaging. Some differential diagnoses were
ruled out by performing minimal autoimmune (antinuclear
factor, anti-DNA, rheumatoid factor, anti-CCP, and ANCA
antibodies) and routine microbiological exams. Serum uric
acid levels were assessed (>6.0mg/dL in women) also taking
account of creatinine level. None of our six patients had a
medical history or other clinical manifestations that evoked
an inherited autoinflammatory syndrome.
For an attack of CRIA, colchicine was given to patients
1 and 6, at 1mg/three times a day, on days 1 and 2; then
1mg twice daily, on days 3 and 4; and then 1mg a day on
days 5 and 6. Reduced doses, for best tolerance with similar
efficacy [2], were given to patients 2 and 4, whereas this
drug was contraindicated in patients 3 and 5 (Table 1). Long-
term prophylaxis was given to patients who had exhibited
previous recurrent attacks of polyarthritis with respect to
renal function [2].The nonsteroidal anti-inflammatory drugs
that were routinely used were indomethacin (orally, 25mg, 3-
4 times daily) or ketoprofen (100mg twice daily, orally and/or
intravenously) given for 10–14 days; doses were reduced by
30% for elderly patients and those at risk of renal damage
with close creatinine monitoring. Prednisone was given
at 0.5mg/kg/day (max. 40mg/day) for 15 days. Anakinra
therapy was maintained until there was both a complete
clinical response and normalization of CRP level. Treatment
with anakinra was stopped by day 6 in the absence of any
clinical improvement and no reduction in CRP level, which
was monitored every 48–72 h.
3. Results
3.1. Main Features of the Patients. Six patients were included
in the study: three patients with crowned dens syndrome
and associated acute/subacute crystal-induced peripheral
arthritis (patients 1, 2, and 3; Table 1; Figure 1) and three other
with gout (patients 4, 5, and 6; Table 1). They were two men
and four womenwith amean age of 72 years, ranging from 65
to 88. Most of them displayed comorbidities such as arterial
hypertension (𝑛 = 4), hypothyroidism (𝑛 = 2), chronic
kidney disease (𝑛 = 2), obesity (𝑛 = 1), diabetes (𝑛 = 1),
and chronic hematological malignancies (MGUS: 𝑛 = 1,
prolymphocytic leukemia: 𝑛 = 1, and polycythemia vera:
𝑛 = 1). All patients exhibited low grade fever, alteration of the
general status, and marked and/or persistent increased CRP
levels over 3 weeks (Table 1).
Patients with crowned dens syndrome were more likely
aged females (three women with mean age of 79 years)
compared to gouty patients (two men, one woman with
mean age of 69.6 years). For the three patients with crowned
dens syndrome, the diagnosis was retained on clinical signs,
namely, fever, multidirectional neck stiffness and pain, exclu-
sion ofmeningitis with lumbar picture in two, and compatible
features of neck CT-scan without any criteria for vertebral
or soft-tissue infectious or tumoral process (Figure 1). The
diagnosis of crowned dens syndrome was moreover based
on concomitant peripheral joint involvements criteria (Table
1). Two patients had, respectively, a history of pseudogout
and HADD diagnosed on typical crystal finding on joint
puncture and compatible X-ray features. The latter exhibited
calcium pyrophosphate crystals on knee joint puncture and
iconographic pictures of pseudogout location, but also thick
arciform calcification of the retrodens ligament on cervical
CT-scan and HADD features on scapular MRI (Figures
1(c)(A) and 1(c)(B)).
Among the three gouty patients, twowere treated, respec-
tively, with hydroxyurea and allopurinol for polycythemia
vera and with pentostatin for a prolymphocytic leukemia
without exhibiting criteria for tumor lysis syndrome; the
latter exhibited severe chronic renal insufficiency related to
gouty nephropathy.
The localization of arthritis was different in the two
groups: gouty patients presented symmetrical large and small
joints arthritis whereas patients with crowned dens syndrome
displayed by definition a periodontoid arthritis and often
asymmetrical shoulder and/or wrist involvements.
3.2. Anakinra Efficacy among Patients with Crowned Dens
Syndrome and Gout. Indication for anakinra was mostly
similar for both groups, including failure or contraindications
to colchicine and/or nonsteroidal anti-inflammatory drugs or
corticosteroids, especially for the associated comorbidities.
Complete remission, defined both clinically and biolog-
ically with the normalization of CRP level (Figure 2), was
obtained in all three gouty patients, whereas for the crowned

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 1: Iconographic features of crowned dens syndrome and crystal-induced peripheral arthritis of patient 1 (a), patient 2 (b), and patient
3 (c(A) and c(B)). (a) Cervical CT-scan centered on the odontoid process: fine linear arciform calcification of the retroodontoid ligament
suggesting pseudogout involvement. (b) Cervical CT-scan centered on odontoid process: cloudlike calcification of the retroodontoid ligament
suggesting hydroxyapatite disease deposition involvement. (c(A)) Cervical CT-scan centered on odontoid process: thick arciform calcification
of the retrodens ligament. (c(B)) Right shoulder MRI (T2 and T1): supraspinatus tendinopathy with partial rupture aspect. Tenosynovitis of
the long biceps. Tendinopathy of the infraspinatus and subscapularis tendons.
dens syndrome group only two of three patients underwent
complete remission with only anakinra. In the crowned dens
syndrome group (patients 1, 2, and 3; Table 1), 9 and 11 days
were, respectively, needed to induce complete remission for
the two responders, whereas in gout only a median of 5 days
(3, 5, and 5 days, resp.) was needed. For the third patient
with crowned dens syndrome, anakinra withdrawal on the
7th day in the context of marked reduction but persistent
neck pains was followed by a rapid disease flare-up 48 h later;
the reintroduction of a second course of anakinra led to
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Figure 2: Evolution of CRP levels on gouty polyarthritis patients
(𝑛 = 3) and crowned dens patients associated with peripheral
pseudogout or hydroxyapatite deposition disease patients (𝑛 =
3) arthritis under anakinra. Normalization of CRP levels at the
3rd or 5th days for the three polyarthritis gouty patients (grey
and dotted lines) associated with complete clinical response and
stopping anakinra. Same but later upcoming for two crowned dens
syndrome patients (black continue lines), respectively, at the 9th
or 11th days of treatment. For the 3rd crowned dens syndrome
patient, early cessation of the treatment stopping within the 7–9th
days (hatched ellipse) showed reincrease of CRP levels; resuming of
anakinra for 11 days showed complete and sustained control of CRP
levels and clinical signs.
rapid, complete, and persistent remission of all acute clinical
signs associated with CRP level normalization at the 11th day,
allowing forwithdrawing the treatment this same day. Finally,
a median of 11 days (9, 11, and 11 days, resp.) was required for
complete remission in crowned dens syndrome patients.
Finally, a gouty patient (patient 6) exhibited a relapse six
weeks after anakinra withdrawal.While the reintroduction of
anakinra did not allow disease control at the 5th day, adjunc-
tion of colchicine led to persistent complete remission at the
3rd day of the combined treatment. For all six patients, after
anakinra withdrawal, dietary recommendations associated
with allopurinol, febuxostat, and/or colchicine were contin-
ued as prophylactic measures; no further relapse occurred
within a follow-up of 6 to 16 months.
3.3. Treatment Safety. Anakinra showed good or excellent
tolerance profiles among all patients. Two patients (patients
1 and 4) had mild injection-site reactions and transient
diffuse pruritus. No episodes of neutropenia or infection
were observed. Despite initial decrease in renal function
(creatinine clearance: 40–20mL/min) in some patients, daily
injections of anakinra were not harmful and even improved
the renal parameters of patient 4 who probably had chronic
gouty nephropathy. Colchicine tolerance was also good,
althoughpatients 2 and 4presented episodic diarrhea. Finally,
for patient 3 who had an ongoing staphylococcal soft-tissue
infection, the use of anakinra rather than colchicine was
harmless.
4. Discussion
In the context of failure or contraindications to conventional
therapies, anakinra exhibited good efficacy in all three types
of CRIA with a longer treatment duration in crowned dens
syndrome and associated peripheral arthritis related to pseu-
dogout and/or HADD (9, 11, and 11 days, resp.) than in gouty
arthritis (3, 5, and 5 days, resp.). Moreover, adjunction of
colchicine to anakinra seems to allow a best outcome in CRIA
refractory to each drug alone. To the best of our knowledge,
this is the first report of anakinra use and efficacy for crowned
dens syndrome related to pseudogout and HADD and also
for HADD peripheral subacute arthritis. The tolerance in
elderly patients was good in our series. Indeed, several articles
showed that anti-IL-1 agents, such as anakinra, are safe in
comparison with other biotherapies, such as anti-TNF-alpha,
considering the risk of tuberculosis reactivation [9, 10].
Only few small series have been reported on the use
of anakinra in gout and pseudogout as curative and/or
prophylactic treatment. Molto´ et al. showed that, in four
out of five patients suffering from refractory subacute
oligo/polyarticular flare-ups of pseudogout, anakinra use for
three days allowed dramatic clinical control and normaliza-
tion of CRP as soon as the third day [6]. Announ et al. and
McGonagle et al. showed similar results for anakinra, used as
a curative or prophylactic treatment for recurrent subacute
or chronic polyarticular pseudogout in two patients for at
least 6 months [5, 11]. Although Couderc et al. reported three
patients with a satisfactory result with anakinra to prevent
acute flare-ups, this drug was unable to control chronic
synovitis symptoms in two of them [7].
Whereas gouty acute/subacute arthritis usually needed
only three days of anakinra treatment, a longer treatment
duration was necessary to control acute pseudogout flare-
ups (14 days for the patient reported by McGonagle et al.)
or chronic synovitis (i.e., at least three months), as observed
for our patients and those in the literature [5, 7]. For two
pseudogout polyarthritis patients, reported by Verhoeven et
al., anakinra prescribed for five days showed no or only slight
response [12].These authors concluded that this poor efficacy
of anakinra might be related to the systemic inflammation
and/or to the long duration of this disease (2–6 months);
these data also correlate with those of Couderc et al. [7].
Considering our pseudogout patients and those reported
by others, this hypothesis appears only partially consistent.
Treatment duration of five days leading to poor efficacy of
anakinra in the series of Verhoeven et al. [12] was much
shorter than the minimum of nine days in our series and
for the patient reported by McGonagle et al. [5]. Thus,
we hypothesize that treatment duration is the major factor
in anakinra success to treat pseudogout and probably also
HADD attacks. Indeed, in the pathophysiology of CRIA, the
key role of IL-1 is nowwell documented: induction of IL-6 and
TNF-alpha upregulation, complex retroinduction of other
cytokines, leading to self-sustaining multicytokine vicious
circle notably in cases of prolonged attacks [13–15].
Deposition of hydroxyapatite crystals in joints and peri-
articular tissues can cause acute attacks, qualified as pseu-
dopodagra, which mimic gout and/or pseudogout attacks
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[13, 16]. Paza´r et al. have shown that, similar to MSU and
CPP, hydroxyapatite crystals can also act as alarmins and
trigger NLRP3 inflammasome activation [13]. The conse-
quent overproduction of IL-1𝛽 seems indirectly mediated by
increased levels of other proinflammatory stimuli, including
TNF-𝛼 or uric acid [17, 18]. Paza´r et al. thus suggested that
the IL-1 blockade may be clinically useful in acute HADD
manifestations; this hypothesis was clinically confirmed for
two of our patients [13]. Adding anakinra to previous ongoing
treatments and, notably, colchicine should lead to the best
response, as seen in the report of McGonagle et al. and for
one of our polyarticular gouty patients [5].
To conclude, IL-1 blockade seems to be an interesting
therapeutic option for all three types of CRIA whatever the
type of joint involvement, including the debilitating and
often misdiagnosed crowned dens syndrome. As observed in
this short series and in sparse literature data, acute/subacute
pseudogout or acute hydroxyapatite deposition arthritis
should require extended duration of treatment with anakinra
than in gouty arthritis [15]. Moreover, adding anakinra to
conventional drugs could show better efficacy than each
drug alone. Therefore, larger studies are needed to best
assess the treatmentmodalities of anakinra in acute/subacute
manifestations of the various types of CRIA, including its
association with conventional drugs in curative and prophy-
lactic purposes.
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